Development of small-molecule inhibitors that target PI3Kβ

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Phosphatidylinositol-3 kinase beta (PI3Kβ) is a critical enzyme in cellular signaling pathways.
• PI3Kβ plays a significant role in the development of PTEN-deficient tumors.
• Dysregulation of PI3Kβ is implicated in thrombosis, male fertility issues, and Fragile X syndrome.

Purpose of the Study:

• To review recent advancements in the development of PI3Kβ-selective inhibitors.
• To explore strategies for achieving isoform selectivity in PI3K inhibition.
• To provide guidance for the development of new clinical candidates targeting PI3Kβ.

Main Methods:

• Focuses on a review of existing literature and research on PI3Kβ inhibitors.
• Discusses three primary strategies for achieving PI3Kβ selectivity: induced lipophilic pocket binding, targeting unique amino acid residues, and employing atropisomerism.
• Analyzes the conformational locking mechanisms for selective PI3Kβ inhibition.

Main Results:

• Several strategies have emerged for developing PI3Kβ-specific inhibitors.
• Targeting PI3Kβ offers a way to mitigate the toxicity associated with pan-PI3K inhibitors.
• Advances in inhibitor design show promise for clinical applications.

Conclusions:

• Selective PI3Kβ inhibition represents a promising therapeutic avenue for various diseases.
• Further development of PI3Kβ-selective inhibitors could lead to more effective and safer treatments.
• The discussed strategies provide a foundation for designing next-generation clinical candidates.